Skip to content

Biohaven launches early-stage study of oral migraine med zavegepant

September 10, 2020

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announces the commencement of dosing in a Phase 1 clinical trial assessing the safety and pharmacokinetics of oral formulations of zavegepant, a third-generation calcitonin gene-related peptide (CGRP) receptor antagonist in development for the potential treatment of migraine.

A month ago, the company secured up to $250M in funding to support its CGRP receptor antagonist program through the development of zavegepant.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: